Tropical ulcer

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Olympus Distribution of EndoClot® Showing Steady Adoption in the U.S.

Retrieved on: 
Friday, March 1, 2024
Static pressure, Traction, Blood, Physician, Tropical ulcer, Dissection, SIS, Polyp, Starch, Hemostasis, Artifact, Internationalized domain name, AMP, Inflammation, Adenoma, Safety, ESD, GI, Water, Classification, Perforated ulcer, CO2, PHS, Patient, Bleeding, Trauma, Perforation, Medical imaging

EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).

Key Points: 
  • EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).
  • Since their launch, EndoClot products have been discussed in close to 20 relevant professional education courses offered via Olympus Continuum, providing physicians with peer-demonstrations of EndoClot technology capabilities during procedures.
  • "Olympus knew that EndoClot technology would be important to improving procedure efficiencies and contributing to improved patient outcomes," said Patrick Romano, Vice President, GI Business Unit Leader, Olympus Corporation of the Americas.
  • A new video highlighting use of the EndoClot PHS and EndoClot SIS has been developed to provide more information: https://www.youtube.com/watch?v=QlCaoiM2Eo0 .

San Jose Wellness Center, NexGen Health, Elevates Wellness Offerings with the Introduction of BPC 157 Peptide Therapy

Retrieved on: 
Wednesday, February 7, 2024
NexGen, IBD, Inflammation, SAN, Tears, Regenerative medicine, Wound, Regeneration, Wound healing, Inflammatory bowel disease, Patient, Irritable bowel syndrome, BPC, Abrasion, Arthritis, IBS, Health, Pain management, Quality of life, Tropical ulcer, Arthralgia

SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services. This cutting-edge therapy is poised to invigorate the body's innate healing processes, offering renewed hope to individuals seeking optimal health and well-being.

Key Points: 
  • NexGen Health improves patient care by introducing BPC 157 peptide therapy in San Jose, California, empowering healing, and wellness.
  • SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services.
  • "Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.
  • Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.

Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen

Retrieved on: 
Tuesday, February 6, 2024
Poster, Product management, OTCQX, QAP, Tropical ulcer, Bacteria, MDX, Ulcer, Diagnosis, Temperature, EQA, Laboratory, TSX, Nobel Prize, QMS, Stomach, Infection, RUO, Accreditation, Helicobacter pylori, Medical device

H. pylori infection was discovered to be the cause of stomach (gastric) ulcers in the 1980’s, in what became a Nobel Prize winning health discovery.

Key Points: 
  • H. pylori infection was discovered to be the cause of stomach (gastric) ulcers in the 1980’s, in what became a Nobel Prize winning health discovery.
  • It is difficult to culture this pathogen, leading to the use of MDx methods for rapid diagnosis.
  • It is sponsored by Labquality Oy, a well-established Scandinavian clinical-lab proficiency and accreditation authority that is a Microbix customer and collaborator (https://www.labquality.com).
  • These H. pylori QAPs are now being made available on a research-use-only (RUO) basis from Microbix as part of its PROCEEDx®FLOQ® catalogue of products.

Standlee® Unveils Smart Carb™ Performance and Forage Plus™ Gastric Support

Retrieved on: 
Thursday, January 18, 2024
Syndrome, Digestion, Insulin resistance, Animal, Health, Molasses, Alfalfa, Disease, Risk, Tropical ulcer, Leaky gut syndrome, Forage, Horse, Starch, Probiotic, Cushing's disease, Intake, Teff, Marketing

KIMBERLY, Idaho, Jan. 18, 2024 /PRNewswire/ -- In a stride towards innovation, Standlee proudly expands its forage-first product offerings with the introduction of Smart Carb™ Performance and Forage Plus™ Gastric Support. Formulated by Dr. Stephen Duren, Ph.D., Equine Nutritionist at Standlee, these blended forage-based pellets are carefully crafted to meet the unique nutritional needs of horses.

Key Points: 
  • Standlee Unveils Smart Carb Performance & Forage Plus Gastric Support: Elevating Equine Nutrition with Forage Blends
    "We are committed to meeting our customers' and their animals' needs, through innovation," said Scott Plew, President of Standlee Premium Products, LLC.
  • Designed to meet consumer demands, Smart Carb & Forage Plus pellets stand out as the perfect supplement for a range of forages.
  • Forage Plus Gastric Support is formulated to buffer stomach acid, support digestive tissue health, and promote a healthy gut microbiome.
  • Standlee continues to prioritize your horse's health and nutritional requirements through innovated products Smart Carb Performance and Forage Plus Gastric Support is available for retailers to order.

Gastroretentive Drug Delivery Systems Outsourcing Market Analysis Report 2023: Increased Focus on Localized Drug Delivery - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023
Health, Pharmaceutical, Research, Disorder, GERD, Investment, Tablet, Administration, Microparticle, USD, Tropical ulcer, COVID-19, IBD, Lonza, Nanotechnology, Gastrointestinal tract, Gastroesophageal reflux disease, Inflammatory bowel disease, Fine chemical, Pharmaceutical industry, Capsule

The "Gastroretentive Drug Delivery Systems Outsourcing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastroretentive Drug Delivery Systems Outsourcing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global gastroretentive drug delivery systems outsourcing market size is expected to reach USD 2.27 billion by 2030.
  • Furthermore, an increased focus on localized drug delivery is expected to boost market growth.
  • Gastroretentive drug delivery systems are indicated for localized drug delivery applications in the gastrointestinal tract.

Vetsource releases continuing education courses in veterinary pharmacy

Retrieved on: 
Thursday, November 30, 2023
Pharmacy technician, Oregon State University, Pharmacist, Student, Pain management, Tropical ulcer, Veterinarian, University, Partnership, Pain, Risk, Knowledge, Nursing, Hospital, Dog, Pharmacy

PORTLAND, Ore., Nov. 30, 2023 /PRNewswire/ -- Vetsource®, a leader in pet pharmacy and technology services, is excited to announce the launch of accredited continuing education courses in veterinary pharmacy.

Key Points: 
  • PORTLAND, Ore., Nov. 30, 2023 /PRNewswire/ -- Vetsource® , a leader in pet pharmacy and technology services, is excited to announce the launch of accredited continuing education courses in veterinary pharmacy.
  • Courses are free of charge to anyone interested in expanding their knowledge of veterinary pharmacy.
  • Conceived by the Vetsource Clinical Committee, which is made up of pharmacists and veterinarians, the courses were developed after the team saw a need for veterinary-specific continuing education.
  • The Vetsource pharmacy team also has a long-standing partnership with Oregon State University to host local pharmacy students on their rotations and share their knowledge of veterinary pharmacy.

Public advisory - Unauthorized health products seized from online retailer "UU Zone" may pose serious health risks

Retrieved on: 
Wednesday, October 25, 2023
Floater, Gland, Stomach, Glaucoma, Viral, Pressure, Health Canada, Dexamethasone, Disease, Risk, Ibuprofen, Allergy, Eye, Red, Nonsteroidal anti-inflammatory drug, Drug identification number, Tuberculosis, Fungal infection, Infection, Sale, Mouth, Burns, Throat, Health, Plasma protein binding, Aspirin, NPN, Rash, Iris cyst, Diabetes, Atrophoderma, Safety, Natural product, Patient, Nose, Prescription drug, Maharashtra University of Health Sciences, Asthma, Triamcinolone, DIN, Pregnancy, Retinal detachment, Pharmacy, Neostigmine, Xeroderma, Cataract, Tropical ulcer, Blurred vision, Herpes simplex, Itch, Skin, Absorption, Inflammation, Common, Hair, NSAID, Myasthenia gravis, Swelling, Weakness, Elasticity, Failure, Dietary supplement, Cosmetics

Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.
  • The products are labelled to contain medicinal drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Read product labels to verify that health products have been authorized for sale by Health Canada.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023
Kidney, Pregnancy, Adrenal insufficiency, Biomarker, EGFR, Vaccine, Glaucoma, Budesonide, American Society of Nephrology, Diabetes, Infection, Ritonavir, CYP3A4, Ciclosporin, Disease, Risk, Capsule, Itraconazole, UPCR, Parasitism, Hypersensitivity, Proteinuria, Alport syndrome, Saquinavir, Measles, Prediabetes, Miscarriage, Immune system, HPA, Ketoconazole, Fetus, CALT, Patient, Anaphylaxis, Tropical ulcer, IgA nephropathy, Indinavir, BAFF, Contraindication, Serum, Cataract, Birth, Administration, Society, Liver, Erythromycin, ASN, Hypertension, Osteoporosis, Immunoglobulin A, Drug interaction, Immunosuppression, Pharmaceutical industry, Dietary supplement, Alport

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.